1. Home
  2. FORA vs NOTV Comparison

FORA vs NOTV Comparison

Compare FORA & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forian Inc.

FORA

Forian Inc.

N/A

Current Price

$2.08

Market Cap

66.2M

Sector

Technology

ML Signal

N/A

Logo Inotiv Inc.

NOTV

Inotiv Inc.

N/A

Current Price

$0.40

Market Cap

12.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FORA
NOTV
Founded
2014
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.2M
12.7M
IPO Year
2020
1997

Fundamental Metrics

Financial Performance
Metric
FORA
NOTV
Price
$2.08
$0.40
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
14.5K
564.7K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
49.64
EPS
N/A
N/A
Revenue
$20,153,263.00
$547,656,000.00
Revenue This Year
$51.82
$5.28
Revenue Next Year
$7.24
$5.42
P/E Ratio
N/A
N/A
Revenue Growth
N/A
511.19
52 Week Low
$1.64
$0.25
52 Week High
$2.71
$3.35

Technical Indicators

Market Signals
Indicator
FORA
NOTV
Relative Strength Index (RSI) 50.16 51.64
Support Level $2.05 $0.26
Resistance Level $2.12 $0.65
Average True Range (ATR) 0.02 0.05
MACD 0.00 0.03
Stochastic Oscillator 60.00 63.79

Price Performance

Historical Comparison
FORA
NOTV

About FORA Forian Inc.

Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

Share on Social Networks: